Brief report · 28 Nov 2025
Research articlePublished 2016
Prognostic Factors in Elderly Patients with Multiple Myeloma Treated with Weekly Bortezomib
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction and objectives: The incidence of multiple myeloma (MM) increases with age. There is a clear decrease in overall survival (OS) in older patients. The purpose of this study was to investigate prognostic factors of MM in this population. Materials and methods: This is an analytic prospective single-center study conducted over 27 months including MM elderly patients treated with weekly subcutaneous bortezomib alone or associated with another chemotherapy. Results: Our work has included 45 patients (median age 84.3 years). Most of them (77.7%) had a PS ≥ 2, 75.6% were undernourished and 57, 1% had a Mini Mental State Examination (MMSE)<26. Haematological grade 3 toxicities were observed in 11% of patients. After 17 months mean follow-up, the median of OS was 18.6 months. In univariate analysis, significant predictors for OS were instrumental activities of daily living (IADL) ≥ 2 (p = 0.003), activities of daily living (ADL)<5 (p = 0.005), the body mass index (BMI)<21 (p = 0.03) and using hospitalization at home unit for bortezomib injections (p = 0.01). In multivariate analysis, significant predictors for OS were ADL<5 (p = 0.005), using hospitalization at home unit (p = 0.007) and IADL ≥ 2 (p = 0.05) Conclusion: In our work, weekly subcutaneous bortezomib was well tolerated. We have shown that functional decline, malnutrition and hospitalization at home unit are predictors of OS. These results lead us to reflect on the need to include these factors in the choice of treatment in elderly patients with MM.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Integrative Oncology.
Brief report · 28 Nov 2025
Biomarkers Predict Integrative Oncology Treatment Response
Opinion · 28 Nov 2025
Navigating Integrative Oncology Trial Design: Innovation and Ethics
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Integrative Oncology
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Anne-Laure Couderc”
- BylineArticles whose byline prints “Bertr”
- BylineArticles whose byline prints “Coutanceau”
- BylineArticles whose byline prints “Roger Mouawad”
- BylineArticles whose byline prints “Bénédicte Mugnier”
- BylineArticles whose byline prints “Amale Chebib”
- BylineArticles whose byline prints “Elodie Baudry”
- BylineArticles whose byline prints “Juliette Spinelli”
